Advertisement

Advertisement

Colorectal Cancer
Breast Cancer
Gynecologic Cancers
Prostate Cancer
Issues in Oncology

Study Evaluates Cancer Screening Behaviors Among a Population of Muslim Individuals

Investigators uncovered crucial insights into the cancer screening behaviors of a population of Muslim individuals residing in the Washington, DC, metropolitan area that could help illuminate the influence of cultural and religious beliefs on health practices, according to a recent study published...

Prostate Cancer
Issues in Oncology

Radioligand Therapy May Improve Radiographic Progression–Free Survival in Taxane-Naive Patients With Advanced Prostate Cancer

Lutetium (Lu)-177–PSMA-617 radioligand therapy may offer a statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with taxane-naive metastatic castration-resistant prostate cancer, according to findings presented by Herrmann et al at the 2024...

Prostate Cancer
Issues in Oncology
Supportive Care

Chelating Agent May Reduce Toxicity Associated With PSMA Radiopharmaceutical Therapy

A novel chelator may significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to new findings presented by Ho et al at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting (Abstract 242340). Background...

Prostate Cancer

Low-Risk Prostate Cancer: Disease-Free Survival With Hypofractionated vs Conventionally Fractionated Radiotherapy

As reported in the Journal of Clinical Oncology by W. Robert Lee, MD, MS, and colleagues, a 12-year analysis of the phase III NRG Oncology RTOG 0415 trial has shown continued noninferiority in terms of disease-free survival with hypofractionated radiotherapy vs conventionally fractionated...

Prostate Cancer

Prostate Cancer: Adjuvant Radiotherapy With 6 Months of ADT vs No ADT

In a component of the phase III RADICALS-HD trial reported in The Lancet, Chris C. Parker, MD, and colleagues found that metastasis-free survival was not significantly improved with 6 months of androgen-deprivation therapy (ADT) vs no ADT together with adjuvant radiotherapy in patients with...

Prostate Cancer

Adjuvant Radiotherapy With 24 vs 6 Months of ADT in Prostate Cancer

In a component of the phase III RADICALS-HD trial reported in The Lancet, Parker et al found that metastasis-free survival was improved with the addition of 24 months vs 6 months of androgen-deprivation therapy (ADT) to adjuvant radiotherapy in prostate cancer. A second component of the trial, not...

prostate cancer

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).

prostate cancer

Alicia Morgans, MD, MPH, and Karim Fizazi, MD, PhD, on Prostate Cancer: Study Findings on Health-Related Quality of Life and Pain

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).

prostate cancer

Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone

Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).

prostate cancer
genomics/genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

prostate cancer

Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).

Prostate Cancer
Issues in Oncology
Genomics/Genetics

Differences in Prostate Cancer Genomics Among U.S. Veterans

Researchers have uncovered differences in the genomic makeup of metastatic prostate cancer cells among U.S. veterans that may be associated with race and ethnicity. These findings will be presented by Valle et al at the 2024 ASCO Annual Meeting (Abstract 5017). The research could translate into...

Prostate Cancer
Issues in Oncology

Sexual Well-Being in the Female Partners of Patients With Prostate Cancer

The female partners of patients with prostate cancer may experience quality-of-life issues that impact their sexual well-being, according to a recent study published by Loeb et al in European Urology Oncology. Background Prostate cancer—one of the most common cancer types in U.S. men—and its...

Prostate Cancer
Supportive Care

Plant-Based Diet May Offer Benefit in Patients With Prostate Cancer

A plant-based diet may help reduce the risk of disease progression in patients with prostate cancer, according to a recent study published by Liu et al in JAMA Network Open. Background Prostate cancer is the most common type of cancer among men. Plant-based diets—which are becoming increasingly...

Prostate Cancer

A Delay in Diagnosis Led to Advanced Prostate Cancer

Cancer is not an unfamiliar disease to me. My mother died of cancer when I was 12. My oldest sister died of breast cancer, an aunt died of cancer (I don’t know which type), and my older brother is a prostate cancer survivor. So, when I was diagnosed with prostate cancer in October 2021, the news...

Prostate Cancer

Whole-Pelvic Radiation Therapy for Unfavorable-Risk Prostate Cancer

As reported in the Journal of Clinical Oncology by Sayan et al, analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy (WPRT) was associated with favorable survival outcomes vs prostate-only radiation therapy (PORT)...

Prostate Cancer
Issues in Oncology

Chemical-Related Epigenetic Modifications May Increase Risk of Prostate Cancer Among Firefighters

Exposure to certain chemicals while on the job may increase the risk of prostate cancer among firefighters, according to a recent study published by Quaid et al in Environmental and Molecular Mutagenesis. Background Prostate cancer has the highest incidence of any cancer type among U.S. male...

Prostate Cancer
Survivorship

Effect of Radiation Therapy Timing on Lifespan of Artificial Urinary Sphincters in Prostate Cancer Survivors

Researchers have shown that adjuvant radiation therapy rather than salvage radiation therapy may improve the function of artificial urinary sphincters for stress urinary incontinence in patients who have undergone surgery for prostate cancer, according to new findings presented by Gaines et al at...

Prostate Cancer

Salvage Reirradiation for Locally Recurrent Prostate Cancer: 7-Year Follow-up

In an update of a Norwegian trial reported in the Journal of Clinical Oncology, Ekanger et al found that long term, salvage reirradiation for locally recurrent prostate cancer was feasible and associated with good outcomes. Study Details The study included 38 patients with locally recurrent disease ...

Prostate Cancer
Supportive Care
Issues in Oncology

Effect of Mindfulness Audio Recordings on Physical, Emotional Side Effects During Radiation Therapy for Prostate Cancer

Listening to mindfulness audio recordings may effectively alleviate the side effects of radiation therapy in men with prostate cancer, according to a recent study published by Victorson et al in Global Advances in Integrative Medicine and Health. Background Men with prostate cancer who receive...

Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer: Addition of LuPSMA to Enzalutamide

In an interim analysis of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved prostate-specific antigen (PSA) progression-free survival in the first-line treatment of patients...

Prostate Cancer
Immunotherapy
Supportive Care

Combination of Preketone Supplements and Immunotherapy May Be Effective in Patients With Prostate Cancer

The addition of a component of the ketogenic diet—a preketone dietary supplement—to immunotherapy showed efficacy in potentially treating prostate cancer in a laboratory setting, according to a recent study published by Murphy et al in Cancer Research. Background Although immune checkpoint blockade ...

Prostate Cancer
Issues in Oncology

Chemohormonal Therapy for Locally Advanced Prostate Cancer

A neoadjuvant chemohormonal therapy combination may offer extended control of prostate-specific antigen (PSA) levels in patients with locally advanced prostate cancer compared with hormonal therapy alone, according to a recent study published by Qian et al in The Journal of Urology. Background...

Prostate Cancer
Issues in Oncology

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer

A novel single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition method using lead (Pb)-212–prostate-specific membrane antigen (PSMA)-based targeted alpha therapy may provide convenient detection of radiopharmaceutical biodistribution and could lead to improved practice ...

Prostate Cancer
Issues in Oncology

Longer Interval May Be Safe for Prostate Cancer Screening in Low-Risk Patients

Undergoing a prostate-specific antigen (PSA) blood test every 5 years may be adequate for screening low-risk men for prostate cancer, according to recent findings presented by Albers et al at the European Association of Urology (EAU) Congress 2024 and simultaneously published in European Urology....

Prostate Cancer
Global Cancer Care

The Lancet Commission on Prostate Cancer: Strategies to Prepare for Predicted Increases in Disease Burden by 2040

Investigators have projected impending increases in the incidence and mortality rates of prostate cancer—especially among individuals in low- and middle-income countries—and proposed new strategies to improve screening, awareness, research diversification, and treatment in a recent The Lancet...

Prostate Cancer
Issues in Oncology

Educational Videos May Encourage Prostate Cancer Screening Among Black Patients

Use of culturally sensitive educational videos may boost knowledge and decrease uncertainty regarding prostate cancer and screening among Black individuals, according to new findings presented by Jones et al at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...

Prostate Cancer
Genomics/Genetics

Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations

Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...

Prostate Cancer
Immunotherapy

Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer

SYNC-T—an investigational therapy that combines a device-induced vaccination at the tumor site with an intratumoral infusion of a multitarget biologic drug—led to numerous clinical responses in patients with metastatic castration-resistant prostate cancer, according to results reported at the...

Prostate Cancer
Issues in Oncology

Benefit of Prostate MRI Plus PSA Density Test in Patients Suspected of Having Prostate Cancer

Investigators have found that combining a prostate magnetic resonance imaging (MRI) scan with a prostate-specific antigen (PSA) density test may help diagnose clinically significant prostate cancer and avoid unnecessary biopsies, according to a recent systematic review and meta-analysis published...

Prostate Cancer
Symptom Management

GU and GI Symptoms With Postprostatectomy Radiotherapy for Prostate Cancer

As reported in JAMA Oncology by Mark K. Buyyounouski, MD, MS, and colleagues, the phase III NRG-GU003 trial showed noninferiority of hypofractionated postprostatectomy radiotherapy (HYPORT) vs conventionally fractionated postprostatectomy radiotherapy (COPORT) for genitourinary (GU) and...

Prostate Cancer

Is Hypofractionated Radiotherapy Emerging as the New Standard of Care After Prostatectomy?

It is currently acknowledged that hypofractionated radiotherapy, an increasingly favored approach in prostate cancer treatment, delivers higher radiation doses over fewer sessions compared with conventional fractionation schedules. This approach is supported by the recognition that prostate cancer ...

Prostate Cancer

Brachytherapy Boost May Decrease the Duration of Androgen-Deprivation Therapy for High-Risk Prostate Cancer

The optimal management of high-risk prostate cancer remains a topic of ongoing investigation. The quest for therapy that maximizes cancer control while minimizing toxicity is constant. Over the past decade, there has been mounting evidence that the addition of a brachytherapy boost to external-beam ...

Prostate Cancer

Localized Prostate Cancer: Association of PSA Nadir Within 6 Months of Radiotherapy With Outcomes

In a study reported in the Journal of Clinical Oncology, Kwak et al found that prostate-specific antigen (PSA) levels ≥ 0.1 ng/mL within 6 months after completion of radiotherapy were prognostic for poorer outcomes in patients with localized prostate cancer who did or did not also receive...

Prostate Cancer

Cabozantinib Plus Atezolizumab Improves Progression-Free Survival

The combination of the tyrosine kinase inhibitor cabozantinib (multiple targets, including MET, AXL, VEGFR2, RET, and FLT ) plus the monoclonal antibody atezolizumab achieved statistically significant improvement in progression-free survival compared with second-line novel hormonal therapy in...

Prostate Cancer
Issues in Oncology

Hormonal Therapy Plus SBRT for Advanced Prostate Cancer

Treatment with a short course of intensified hormonal therapy in combination with metastasis-directed stereotactic body radiation therapy (SBRT) may be safe and effective in patients with oligorecurrent and metastatic prostate cancer, according to a recent study published by Nikitas et al in...

Prostate Cancer

Localized or Advanced Prostate Cancer: Short- or Longer-Term Relugolix Plus Radiotherapy

In an analysis reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that treatment with relugolix was associated with rapid achievement of sustained castration in patients with localized or advanced prostate cancer who were also receiving radiotherapy. Study Details The analysis...

Prostate Cancer

Patients With Biochemical Recurrence of Prostate Cancer: Ga-68–RM2 PET-MRI vs MRI Alone for Lesion Detection

In a single-center phase II/III imaging trial reported in The Lancet Oncology, Duan and colleagues found that gallium Ga-68–labeled RM2 (Ga-68–RM2) positron-emission tomography (PET)-magnetic resonance imaging (MRI) outperformed MRI alone in positive findings and number of lesions detected in...

Prostate Cancer

Expert Point of View: Kim N. Chi, MD

Formal discussant of the BRCAAway trial, Kim N. Chi, MD, of the British Columbia Cancer–Vancouver Center, University of British Columbia, Canada, said this study supports the use of PARP inhibitors in patients with metastatic castration-resistant prostate cancer and homologous recombination–repair...

Prostate Cancer

Olaparib Plus Abiraterone and Prednisone Improves Outcomes Over Single Agents in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

First-line treatment with the PARP inhibitor olaparib plus the androgen biosynthesis inhibitor abiraterone acetate and the steroid prednisone improved progression-free survival and response rates compared with either treatment alone (ie, olaparib or abiraterone plus prednisone) in patients with...

Prostate Cancer
Issues in Oncology

AUA, ASTRO, SUO Release Clinical Practice Guidelines on Salvage Therapy for Prostate Cancer

The American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released new clinical practice guidelines on salvage therapy for patients with prostate cancer. These guidelines were reported on by Morgan...

Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer: Tumor Mutational Burden and Response to Checkpoint Inhibition

In a single-center retrospective study reported as a research letter in JAMA Oncology, Zang et al found that high tumor mutational burden (TMB) was associated with better outcomes of checkpoint inhibition in patients with metastatic castration-resistant prostate cancer.  Study Details The study...

Prostate Cancer

Rapid Guideline Update on Radiotracers for Determining Radioligand Treatment Eligibility in Metastatic Castration-Resistant Prostate Cancer

ASCO has released a guideline rapid recommendation update addressing radiotracers used for prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) diagnostic imaging for selecting patients with metastatic castration-resistant prostate cancer (mCRPC) to receive...

Prostate Cancer
Issues in Oncology

Racial Representation Affects Trust for Black Patients Seeking Prostate Cancer Information Online

Among Black patients with prostate cancer, racial representation may be a key factor affecting their trust in websites offering information on the disease, according to a recent study published by Loeb et al in The Journal of Urology. Background Black men may have higher rates of prostate cancer...

Prostate Cancer
Symptom Management
Supportive Care

Plant-Based Diet May Be Linked to Improved Sexual Health in Men Treated for Prostate Cancer

Plant-based diets may be linked to a lower risk of erectile dysfunction, urinary incontinence, and other common side effects experienced by patients receiving treatment for prostate cancer, according to a new study published by Loeb et al in Cancer. The findings indicated that nutrition may lead to ...

Prostate Cancer

High-Risk Localized Prostate Cancer: Survival Benefit With Long-Term ADT and Dose-Escalated Radiation Therapy

Men with high-risk localized prostate cancer had a significant survival benefit when treated with a more intensified regimen of dose-escalated radiation therapy plus long-term androgen-deprivation therapy (ADT) vs standard radiation therapy plus ADT, according to long-term follow-up from the...

Prostate Cancer

Localized Prostate Cancer: Functional Outcomes After Specific Treatments

In an observational cohort study reported in JAMA, Al Awamlh et al identified adverse functional outcomes after localized prostate cancer treatment among patients with favorable- and unfavorable-prognosis disease.  Study Details The study included 2,445 patients from five SEER (Surveillance,...

Issues in Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer

Insufficiencies Discovered in Patient-Reported Outcomes Data From Genitourinary Cancer Clinical Trials

Investigators may have found a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials, according to a recent study published by Paravathaneni et al in eClinicalMedicine. Background Genitourinary cancers affect over 444,000...

Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer: LuPSMA vs Cabazitaxel

As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, the Australian phase II TheraP trial has shown similar overall survival with lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) vs cabazitaxel in patients with prostate-specific membrane...

Prostate Cancer

Intensification of ADT in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer After Radical Prostatectomy

As reported in the Journal of Clinical Oncology by Aggarwal et al, interim analysis of the phase III PRESTO trial showed that the addition of apalutamide as well as the addition of apalutamide plus abiraterone acetate/prednisone (AAP) to androgen-deprivation therapy (ADT) improved prostate-specific ...

Advertisement

Advertisement

Advertisement